Valued at a market cap of $204.3 billion, Merck & Co., Inc. (MRK) is a global healthcare company with a diverse portfolio ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

WHITEHOUSE STATION, N.J. (CBS.MW) - Shares of Dow component Merck & Co. rose nearly 10 percent on Monday after the drug maker reported stronger-than-expected second-quarter earnings. Merck (MRK ...

Merck has released data and updates for several trials heading into its second quarter earnings report. Shares of the stock are now down year-to-date after turning out a positive gain in the first ...

Merck appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Merck & Co.’s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant’s earnings later this month, though the talks remain on track, according to ...

Merck is set to announce its second-quarter results later this month, ... What You Need To Know Ahead of Merck's Earnings Release. Sohini Mondal . Wed, Jul 9, 2025, 11:17 AM 2 min read.

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.